Suboxone 2mg

Buy Suboxone 2mg Tablets Research Chemical Online – USA, Europe & Worldwide

Welcome to RChems EU, a globally trusted supplier of high-purity research chemicals serving academic, pharmaceutical, and forensic laboratories across five continents. Our Suboxone 2mg Tablets (Buprenorphine/Naloxone combination) offer researchers a standardized, analytically verified reference material for forensic toxicology, opioid receptor pharmacology, and analytical method development.

Suboxone is a fixed-dose combination tablet containing buprenorphine (a semi-synthetic opioid partial agonist) and naloxone (an opioid antagonist). As a research chemical, this combination serves as a unique reference standard for studying partial agonist/antagonist interactions at μ-opioid receptors (MOR), evaluating opioid receptor occupancy, and developing analytical methods for the simultaneous quantification of both compounds in biological matrices. Buprenorphine exhibits high-affinity partial agonism at MOR with a characteristic ceiling effect, while naloxone acts as a competitive antagonist, blocking opioid effects. This combination provides a valuable tool for researchers investigating opioid dependence mechanisms, receptor pharmacology, and forensic identification of opioid use disorder medications.

When you buy Suboxone 2mg tablets for research from RChems EU, you receive a rigorously synthesized, analytically verified reference material at ≥99% purity for both active ingredients. Each tablet delivers a precise 2mg dose of Buprenorphine and 0.5mg of Naloxone, eliminating weighing variability and providing a consistent matrix-matched calibration standard for laboratory analysis. Whether your laboratory is located in the USA, Germany, Japan, Australia, or Brazil, our worldwide logistics network ensures rapid, discreet delivery directly to your institutional address.

Key Features & Benefits

• ≥99% Verified Purity: Every batch undergoes independent orthogonal testing using HPLC-DAD, ¹H/¹³C NMR, and LC-MS/MS for both buprenorphine and naloxone. Total impurities are maintained below 1% for each active ingredient, ensuring reproducible results.
• Standardized Fixed-Dose Combination Format: Pre-dosed, homogeneous tablets containing a precise 2mg buprenorphine/0.5mg naloxone ratio eliminate the need for separate weighing and mixing of two distinct compounds. Ideal for dissolution testing, calibration curve generation, and combination reference standards.
• Discreet & Secure Packaging: Plain, unmarked outer boxes with zero chemical identifiers. Vacuum-sealed inner blister packs protect against moisture, oxidation, and tampering. No mention of “Suboxone,” “buprenorphine,” “naloxone,” or “research chemical” on any external shipping label or customs declaration.
• Fast Worldwide Delivery: Strategic dispatch hubs in the European Union and United States. Typical transit: 3–7 business days to USA, UK, and Canada; 5–12 days to Australia, New Zealand, and Japan; 7–14 days to South America and South Africa.
• Batch-Specific Certificate of Analysis (CoA): Every order includes a detailed CoA with chromatograms, retention times, purity percentage for both compounds, residual solvent analysis, and heavy metals testing. Full analytical data available upon request prior to purchase.
• Flexible Quantity Options: Available in 60, 120, 180, 240, or 300 tablet quantities to suit studies of any scale.

Product Specifications

Applications & Usage

Suboxone 2mg Tablets are strictly intended for forensic, analytical, and in-vitro research applications only. Typical laboratory uses include:

• Forensic Toxicology Reference Standard: Employ as a certified comparison material for the identification and quantification of buprenorphine, norbuprenorphine, and naloxone in biological matrices (blood, urine, tissue) using LC-MS/MS, GC-MS, or HPLC-DAD in accredited forensic laboratories.
• Analytical Method Development & Validation: Utilize matrix-matched tablets to develop and validate extraction protocols, calibration curves, and quality control procedures for simultaneous quantification of buprenorphine and naloxone in clinical and forensic settings.
• Opioid Receptor Binding Assays: Investigate buprenorphine’s partial agonist activity and naloxone’s antagonist effects at μ-opioid (MOR), κ-opioid (KOR), and δ-opioid (DOR) receptors using radioligand displacement (e.g., [³H]-DAMGO for MOR) or functional GTPγS binding assays in transfected cell lines or native membrane preparations.
• Combination Pharmacology Studies: Characterize the interaction between a partial agonist (buprenorphine) and a competitive antagonist (naloxone) at opioid receptors, including studies on receptor occupancy, internalization, and downstream signaling.
• Pharmacokinetic Reference Material: Serve as a certified standard for in-vitro permeability studies (Caco-2, MDCK), plasma protein binding assays, and metabolic stability profiling using human liver microsomes (HLM) or recombinant CYP450 isoforms (primarily CYP3A4 for buprenorphine).
• Dissolution Testing & Quality Control: Use as a reference material for dissolution testing apparatus calibration and pharmaceutical quality control method development for combination products.
• Stability Indicating Studies: Employ in forced degradation studies (thermal, photolytic, hydrolytic, oxidative) to identify degradation products of both buprenorphine and naloxone and validate stability-indicating HPLC methods.

Researchers are strongly encouraged to follow institutional chemical hygiene plans and consult peer-reviewed literature for comparative pharmacological data. This product is not for in-vivo administration in vertebrate animals without explicit IACUC approval specifically citing its use as a reference standard.

Purity & Testing

At RChems EU, we understand that research reproducibility begins with compound integrity. Every batch of 99% pure Suboxone 2mg tablets undergoes a comprehensive, multi-tiered analytical workflow before release:

1. High-Performance Liquid Chromatography (HPLC-DAD): Quantifies purity of both buprenorphine and naloxone against certified reference standards at dual wavelengths (210 nm for buprenorphine, 230 nm for naloxone). Acceptance criterion: ≥99.0% main peak area for each compound. All impurities ≥0.05% are reported with retention times.
2. Liquid Chromatography-Mass Spectrometry (LC-MS/MS): Confirms molecular ions [M+H]⁺ at m/z 468.3 (buprenorphine) and m/z 328.2 (naloxone) with characteristic fragmentation patterns. Rules out isobaric contaminants and synthetic byproducts.
3. Nuclear Magnetic Resonance (¹H and ¹³C NMR): Unambiguously confirms structural identity of both compounds, including the oripavine skeleton of buprenorphine and the morphinan core of naloxone. Verifies absence of unexpected synthetic intermediates or stereoisomers.
4. High-Resolution Mass Spectrometry (HRMS-TOF): Provides exact mass measurement (buprenorphine: calculated 467.3036, observed 467.3034 ± 2 ppm; naloxone: calculated 327.1471, observed 327.1469 ± 2 ppm) to rule out isobaric contaminants and confirm elemental composition.
5. Karl Fischer Coulometry: Ensures moisture content below 0.5%, critical for long-term stability of the tablet matrix.
6. Content Uniformity Testing (USP <905>): Random sampling of 10 tablets from each batch ensures each individual tablet contains 2mg buprenorphine ± 10% and 0.5mg naloxone ± 10%, with relative standard deviation (RSD) <6% for each.
7. Residual Solvent Analysis (GC-FID): Quantifies residual organic solvents from synthesis per ICH Q3C guidelines.
8. Dissolution Testing (USP <711>): Performed on representative samples to ensure consistent release characteristics for dissolution method development.

Only batches that pass all eight checkpoints are released for distribution. This rigorous approach means when you buy Suboxone for research from Alpha Lab Chems, you eliminate batch-to-batch variability—a primary cause of non-reproducible results in opioid pharmacology and forensic toxicology.

Safety & Handling Guidelines

WARNING: For research use only. Not for human or animal consumption, therapeutic application, veterinary use, or any form of in-vivo administration outside approved controlled substance protocols.

• Personal Protective Equipment (PPE): Nitrile gloves (double-gloving recommended), laboratory coat, and chemical splash goggles mandatory when handling tablets or any dissolved solutions. Replace gloves immediately if contaminated.
• Ventilation: All manipulations must be performed inside a certified chemical fume hood or glove box. Avoid crushing tablets or generating airborne particulates. Use HEPA-filtered vacuum for spill cleanup.
• First Aid – Skin Contact: Wash immediately with copious soap and water for at least 15 minutes. Remove contaminated clothing. Seek medical evaluation if irritation develops.
• First Aid – Eye Contact: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing for at least 15 minutes. Seek immediate medical attention.
• First Aid – Inhalation: Move to fresh air immediately. Administer oxygen if breathing difficulty occurs. If breathing has stopped, perform artificial respiration. Seek immediate medical attention.
• First Aid – Accidental Ingestion: Do not induce vomiting. Rinse mouth with water. Seek immediate emergency medical care and provide this Safety Data Sheet (SDS) to treating physician.
• Spill Management: Isolate area, restrict access. Wearing full PPE, collect tablets mechanically using a dustpan and brush into a sealed hazardous waste container. Decontaminate surfaces with 70% ethanol followed by soap and water.
• Disposal: Comply with all local, state, and federal regulations for opioid derivatives and research chemicals. Incineration via a licensed hazardous waste vendor is strongly recommended.

Global Shipping & Discreet Delivery

RChems EU prioritizes your privacy, your research continuity, and the integrity of your supply chain. Our shipping protocols are engineered to attract zero unnecessary attention from customs, couriers, or third parties.

• Plain Outer Packaging: Standard corrugated cardboard boxes or Tyvek padded envelopes. No company logos, no chemical names, no hazard diamonds. Return address is a generic “Fulfillment Department” or “Logistics Center” with no mention of RChems EU.
• No Chemical Identifiers on Labels: Shipping labels and commercial invoices never list “Suboxone,” “buprenorphine,” “naloxone,” “opioid,” or “research chemical.” Typical customs descriptions: “Laboratory consumables,” “Non-hazardous solid reference material,” “Inert polymer samples for analysis,” or “In vitro diagnostic reagents (non-human).”
• Vacuum-Sealed & Tamper-Evident: Each blister pack is heat-sealed in food-grade mylar, then vacuum-sealed a second time in an opaque outer pouch. Eliminates moisture ingress and evidence of tampering. Seals show visible evidence if opened during transit.
• Worldwide Coverage: We ship to all 50 US states (where local law permits research use), Canada, United Kingdom, EU Schengen zone, Switzerland, Norway, Australia, New Zealand, Japan, South Korea, and South Africa.
• Real-Time Tracking: DHL Express, FedEx Priority, or UPS Worldwide tracking number provided within 24 hours of dispatch. All shipments are insured for full commercial value against loss or damage.

Shipping Tiers:
| Service Level | Transit Time | Cost | Features |
| :— | :— | :— | :— |
| Standard International Airmail | 10–20 business days | Free on orders >$250 | Tracking available in select countries, no signature required |
| Express Courier (DHL/FedEx/UPS) | 3–7 business days | Calculated at checkout | Insured, signature required, real-time GPS tracking |

Why Choose RChems EU?

• Verified ≥99% Purity: Independent batch testing via HPLC, LC-MS, NMR, and HRMS for both active compounds. No vague claims. Every CoA includes raw chromatograms, spectra summaries, and quantitative impurity data.
• Stealth Packaging Industry Standard: Over 10,000 successful deliveries to research institutions worldwide. Zero customs seizures directly attributable to packaging or labeling failure in the past 36 months.
• Fast Fulfillment: Orders placed before 2 PM EST (Monday–Friday) ship same business day. Weekend orders ship Monday. Tracking provided within 24 hours.
• Scientific Support Team: Available 6 days/week (Monday–Saturday) to answer solubility questions (e.g., “Best solvent for extracting buprenorphine and naloxone?”), stability inquiries, analytical method troubleshooting, and CoA interpretation.
• Flexible Quantities: Choose from 60, 120, 180, 240, or 300 tablets to match your research scale.
• Ethical Compliance Program: We actively screen for residential addresses and require institutional affiliation verification (university, research institute, or corporate R&D email domain) for all restricted research products. We do not sell to individuals in prohibited jurisdictions.

Legal & Safety Disclaimer

IMPORTANT – READ CAREFULLY BEFORE ORDERING:

Suboxone contains buprenorphine (a Schedule III controlled substance in the USA) and naloxone (a non-controlled prescription drug). Depending on jurisdiction, this combination may be classified as a controlled substance, prescription-only medicine, or research chemical subject to strict import/export restrictions. Specific legal statuses include:

• United States: Buprenorphine is a Schedule III controlled substance under the Controlled Substances Act (21 U.S.C. § 812). Naloxone is not scheduled. Legitimate in-vitro research use by licensed institutions with appropriate DEA registration and research exemptions may be permitted for the buprenorphine component. Researchers must possess all required licenses and registrations.
• United Kingdom: Buprenorphine is a Class C controlled substance under the Misuse of Drugs Act 1971.
• Germany: Buprenorphine is controlled under the Betäubungsmittelgesetz (BtMG).
• Australia: Buprenorphine is a Schedule 8 (Controlled Drug) under state and territory poisons standards.
• Canada: Buprenorphine is a Schedule I controlled substance under the Controlled Drugs and Substances Act (CDSA).

RChems EU sells Suboxone 2mg Tablets strictly as a research chemical and analytical reference standard for in-vitro laboratory use only. This product is not for human or animal consumption, personal use, clinical application, self-medication, addiction treatment, or any form of in-vivo administration. No medical, therapeutic, or opioid-use-disorder treatment claims are made or implied.

By purchasing this product, you affirm, warrant, and legally bind yourself to the following:

• You are at least 18 years of age (21 years in certain jurisdictions including California and New York for research chemical purchases).
• You are a qualified researcher affiliated with a recognized academic institution, pharmaceutical company, forensic laboratory, contract research organization (CRO), or government agency.
• You possess any and all required licenses, permits, research exemptions, DEA registration (or equivalent national authority), and import authorizations necessary for the lawful acquisition, possession, storage, and handling of the controlled substances contained in this product in your country, state, province, or territory.
• You will not transfer, resell, distribute, or otherwise provide this product to any third party without explicit written authorization from RChems EU.
• You will use this product exclusively as an analytical reference standard for legitimate scientific research purposes and in compliance with all applicable institutional, local, state, and federal laws, regulations, and guidelines.
• You will not attempt to consume, ingest, inhale, inject, or otherwise introduce this product into a living organism.

RChems EU reserves the right to refuse, cancel, or refund any order at its sole discretion, including but not limited to orders from residential addresses, P.O. boxes, freight forwarders, proxy services, or jurisdictions where buprenorphine is explicitly prohibited without a license. No refunds will be issued for shipments seized by customs where the buyer failed to verify import legality and obtain required licenses prior to ordering. International buyers assume all risks associated with cross-border shipping, including seizure, delay, or destruction by customs authorities.

FAQ Section

Q1: What is Suboxone 2mg used for in research?
A: Suboxone is a fixed-dose combination tablet containing buprenorphine (a semi-synthetic opioid partial agonist) and naloxone (an opioid antagonist). In research settings, it is used as an analytical reference standard for forensic toxicology (LC-MS/MS, GC-MS method development and calibration for simultaneous quantification of buprenorphine, norbuprenorphine, and naloxone), opioid receptor binding assays (studying partial agonist/antagonist interactions at μ, κ, and δ receptors), combination pharmacology research, in-vitro permeability and metabolic stability studies (Caco-2, human liver microsomes), dissolution testing method development, and stability-indicating assays. It is not for human or animal consumption.

Q2: Is Suboxone legal to buy for research?
A: Suboxone contains buprenorphine, a Schedule III controlled substance in the USA and similarly controlled in most other countries. Legitimate in-vitro research use by licensed institutions with appropriate DEA registration (or equivalent national authority) and research exemptions may be permitted. You are solely responsible for verifying your local laws and obtaining any required licenses, permits, or registrations before ordering. RChems EU will not ship to jurisdictions without proper authorization. Contact our compliance team with your institutional affiliation and license documentation for a jurisdiction-specific assessment.

Q3: How discreet is your shipping packaging?
A: Extremely discreet. The outer package is a plain, unmarked box or padded envelope with no branding, no chemical names, no hazard warnings, and no logos. The return address is a generic “Fulfillment Department” or “Logistics Center” with no mention of RChems EU or “research chemicals.” The customs declaration lists only generic, non-suspicious terms such as “laboratory consumables,” “non-hazardous solid reference material,” or “in vitro diagnostic reagents (non-human).” Inside, the tablets are sealed in an opaque, vacuum-sealed blister pack with no external labeling. Even the courier tracking page shows only a nondescript sender name. We maintain strict compliance with all applicable shipping regulations for controlled substances to licensed researchers.

Q4: What is the exact purity level, and how is it tested?
A: Minimum 99% pure for both buprenorphine and naloxone as determined by HPLC-DAD at optimized wavelengths (210 nm for buprenorphine, 230 nm for naloxone). Each batch’s Certificate of Analysis includes the exact purity percentage for each compound (typically 99.2–99.6%), representative chromatograms showing separation of both peaks, LC-MS/MS total ion chromatogram, ¹H and ¹³C NMR spectrum summaries for each compound, residual solvent profile, heavy metals analysis, and moisture content. We use orthogonal analytical methods (HPLC + LC-MS + NMR + HRMS) to confirm both identity and purity of each active ingredient. No batch with any single unspecified impurity exceeding 0.2% for either compound is ever released for sale.

Q5: How should I store Suboxone 2mg tablets after opening?
A: Store in the original sealed blister pack or transfer immediately to a tight, amber glass vial with a desiccant packet (silica gel, 3–5 grams). Keep at controlled room temperature (15–25°C / 59–77°F), away from direct sunlight, heat sources, open flames, oxidizing agents, and humidity exceeding 60%. Do not refrigerate or freeze, as condensation upon opening may degrade tablet integrity. Under proper storage conditions, chemical stability remains ≥98% for both compounds for 36 months from the date of manufacture. Always allow the sealed container to reach room temperature before opening to minimize moisture uptake.

Q6: What quantity options are available?
A: Suboxone 2mg Tablets are available in five quantity options: 60 tablets, 120 tablets, 180 tablets, 240 tablets, or 300 tablets. This flexibility allows researchers to order appropriate amounts for pilot studies, full-scale experiments, or long-term reference standard storage. Volume discounts apply to larger quantities.

Q7: Can I receive a Certificate of Analysis before placing an order?
A: Absolutely. Contact our scientific support team with the product name (Suboxone 2mg Tablets), your institutional affiliation, DEA registration or equivalent license number (if applicable), and intended research application. We will provide a representative CoA from the current or most recent production batch, including HPLC purity percentages for both buprenorphine and naloxone, impurity profiles, chromatograms showing separation of both compounds, and NMR summaries. Full, lot-specific CoAs are included inside every shipment.

Q8: Are the tablets suitable for use as analytical standards for both compounds?
A: Yes. These tablets are manufactured with pharmaceutical-grade excipients to provide a consistent matrix-matched reference material for both buprenorphine and naloxone simultaneously. For quantitative analysis, we recommend extracting both compounds from the tablet matrix using an appropriate solvent (e.g., methanol or acetonitrile) and comparing against certified neat reference standards for absolute quantification. The fixed-dose combination format is ideal for developing methods that require both analytes, such as simultaneous LC-MS/MS quantification.

Q9: What is the rationale for the buprenorphine/naloxone combination in research?
A: In research contexts, the buprenorphine/naloxone combination allows investigators to study the interaction between a partial μ-opioid receptor agonist (buprenorphine) and a competitive opioid antagonist (naloxone). This combination is of pharmacological interest because naloxone is included to antagonize the effects of buprenorphine, serving as a model system for studying partial agonist/antagonist interactions at opioid receptors, receptor occupancy dynamics, and the pharmacological ceiling effect of partial agonists.

Q10: Can I request a different dosage or larger quantity?
A: For research institutions requiring alternative dosages (e.g., buprenorphine 4mg/naloxone 1mg tablets, or individual component standards) or larger quantities (500+ tablets), please contact our institutional sales team. We offer custom formulation and tableting services with the same ≥99% purity guarantee and full analytical testing (HPLC, LC-MS, NMR, HRMS) for both active ingredients. Minimum order quantities vary. Contact us for a quotation and to discuss your specific research requirements.

Q11: What solvents are recommended for extracting Buprenorphine and Naloxone from the tablet matrix?
A: For analytical extraction, methanol or acetonitrile are recommended. Typical procedure: Place one tablet in a volumetric flask, add 10 mL of methanol, sonicate for 15–20 minutes, then dilute to volume. Filter through a 0.45 µm PTFE filter before injection. For receptor binding assays, extract with DMSO to prepare stock solutions (e.g., 10 mM buprenorphine, 2.5 mM naloxone based on tablet ratio), then dilute in assay buffer (final DMSO concentration <0.1%). Ensure complete extraction by verifying recovery against certified neat reference standards for both compounds.

Ready to advance your forensic toxicology and opioid receptor research? Order Suboxone 2mg Tablets today from RChems EU – where purity, precision, and discretion define every shipment.

For institutional inquiries, standing purchase orders, DEA-registered facilities, or custom dosing formats, please contact our scientific sales team. Valid research credentials and applicable licenses are required prior to shipment.